Dr Reddy's, Cipla lag behind BSE Healthcare index despite product launches
The story in brief
Dr Reddy's Labs and Cipla underperformed the BSE Healthcare index, with Dr Reddy's revenue down 5.6% YoY to ₹8,070.5 crore and Cipla's North America sales falling 21% to ₹1,532 crore. Dr Reddy's launched generic semaglutide in Canada and India, and a GLP-1 product with Nestle. Cipla's Yurpeak became the second-largest obesity drug, generating ₹80 crore. Analysts cut earnings forecasts for both by 6-8% for FY27 and FY28, citing a tough business environment.